Surís X, Pueyo-Sánchez M J, Ricart A, Naranjo A, Casanova T, Gómez-Vaquero C, Duaso E, Cancio-Trujillo J M, Sánchez-Martín J, Pérez-Mitru A
Departament de Salut, Pla director de les malalties reumàtiques i de l'aparell locomotor, Barcelona, España; Servicio de Reumatología, Hospital General de Granollers, Barcelona, España; Facultat de Medicina i Ciències de la Salut, Universitat Internacional de Catalunya, Sant Cugat del Vallès, Barcelona, España; Gerència de Processos Integrats en Salut, Àrea Assistencial, Servei Català de la Salut, Barcelona, España.
Àrea Integral de Salut Barcelona Esquerra, Consorci Sanitari de Barcelona, Regió Sanitària Barcelona, Servei Català de la Salut, Barcelona, España.
J Healthc Qual Res. 2024 Jul-Aug;39(4):205-213. doi: 10.1016/j.jhqr.2024.03.004. Epub 2024 Apr 12.
To assess the cost-effectiveness of Fracture Liaison Service (FLS) compared to the standard of care for secondary prevention of fragility fractures form the perspective of the Catalan Health Service.
Cost-utility assessment through a Markov model that simulated disease progression of a patients' cohort candidates to initiate antiosteoporotic treatment after a fragility fracture. A time horizon of 10 years and a 6-month duration per cycle was established. Clinical, economics and quality of life parameters were obtained from the literature and derived from four Catalan FLS. The Catalan Health Service perspective was adopted, considering direct health costs expressed in 2022 euros. A 3% discount rate was applied on costs and outcomes. Uncertainty was assessed through multiple sensitivity analyses.
Compared to the standard of care, FLS would promote antiosteoporotic initiation and persistence, reducing the incidence and mortality associated with subsequent fragility fractures. This incremental clinical benefit was estimated at 0.055 years and 0.112 quality-adjusted life years (QALYs) per patient. A higher cost (€1,073.79 per patient) was estimated, resulting into an incremental cost-utility ratio of €9,602.72 per QALYs gained. The sensitivity analyses performed were consistent, corroborating the robustness and conservative approach of the base-case.
The introduction of FLS for the secondary prevention of FF would represent a cost-effective strategy from the Catalan Health Service perspective.
从加泰罗尼亚卫生服务的角度评估骨折联络服务(FLS)与脆性骨折二级预防标准治疗的成本效益。
通过马尔可夫模型进行成本效用评估,该模型模拟了一组脆性骨折后开始抗骨质疏松治疗的患者队列的疾病进展。设定了10年的时间范围,每个周期持续6个月。临床、经济和生活质量参数来自文献,并取自四个加泰罗尼亚FLS。采用加泰罗尼亚卫生服务的视角,考虑以2022欧元表示的直接医疗成本。对成本和结果应用3%的贴现率。通过多次敏感性分析评估不确定性。
与标准治疗相比,FLS将促进抗骨质疏松药物的起始和持续使用,降低与后续脆性骨折相关的发病率和死亡率。估计每位患者的这种增量临床效益为0.055年和0.112个质量调整生命年(QALY)。估计成本更高(每位患者1073.79欧元),导致每获得一个QALY的增量成本效用比为9602.72欧元。所进行的敏感性分析结果一致,证实了基础案例的稳健性和保守性。
从加泰罗尼亚卫生服务的角度来看,引入FLS进行FF的二级预防将是一种具有成本效益的策略。